Decitabine

Measurable residual disease monitoring in AML

Top Biomedical Science shared on X:

“Measurable residual disease monitoring in AML:

Prospects for therapeutic decision-making and new drug development.”

Source: Top Biomedical Science/X

Measurable residual disease monitoring in AML: Prospects for therapeutic decision-making and new drug development

Authors: Nicholas J. Short, Richard Dillon

disease

AML cancer drug development leukaemia Nicholas J. Short OncoDaily Oncology residual disease monitoring Richard Dillon Top Biomedical Science